We are live on ! Find out more
COCHW icon

Envoy Medical Warrant
COCHW

61 hedge funds and large institutions have $2.12M invested in Envoy Medical Warrant in 2023 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 7 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

2% less funds holding

Funds holding: 6261 (-1)

9% less capital invested

Capital invested by funds: $2.34M → $2.12M (-$213K)

20% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 5

57% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 7

Holders
61
Holders Change
-1
Holders Change %
-1.61%
% of All Funds
0.96%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
4
Increased
3
Reduced
7
Closed
5
Calls
$83K
Puts
Net Calls
+$83K
Net Calls Change
-$6.15M

COCHW Hedge Fund Activity: Q2 2023 in Review

61 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Envoy Medical Warrant (COCHW) for Q2 2023, worth a combined $2.12M — down 9.1% from $2.34M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of COCHW and 4 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 3 added.

The largest buyer was Man Group, opening a new position worth an estimated $14.1K. The largest seller was StoneX Group, cutting an estimated $5.55K.

  • 61 institutional investors held Envoy Medical Warrant (COCHW) as of Q2 2023, down from 62 in Q1 2023.
  • Funds reported $2.12M of Envoy Medical Warrant stock for Q2 2023, down 9.1% quarter-over-quarter.
  • 4 funds opened new Envoy Medical Warrant positions in Q2 2023 and 5 closed out, a net change of -1 holder.
  • The largest Envoy Medical Warrant buyer in Q2 2023 was Man Group, an estimated $14.1K added.
  • The largest Envoy Medical Warrant seller in Q2 2023 was StoneX Group, an estimated $5.55K sold.

Based on aggregated 13F filings for Q2 2023.